Skip to main content
    V

    Viridian Therapeutics Inc (VRDN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $30.06
    +0.26 (+0.87%)

    Market Cap: $3.51B

    Last updated: Nov 17, 2026 at 4:14 PM ET

    Viridian Therapeutics Inc (VRDN) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Viridian Therapeutics (VRDN) has a market cap of $3.51B and an enterprise value of $3.58B. It kept -1724.06% of revenue as net income over the last 12 months. Its share count is up 38.67% from a year earlier.

    Total Valuation

    Enterprise value is 2.01% above the market cap, as debt exceeds cash.

    Market Cap$3.51B
    Enterprise Value$3.58B
    Latest price (Nov 17, 2026)$30.06

    Key Dates

    The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 24, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 5.12% in the quarter ended Sep 30, 2026 and grew 30.67% a year over 2 years.

    Shares Outstanding113.41M
    Shares Change (YoY)+38.67%
    Shares Change (QoQ)+5.12%
    Share Count Growth (2Y CAGR)+30.67%

    Valuation Ratios

    Sales and book value multiples are 129.6x and 5.9x. Its year-end P/S ranged from 2.0x to 526.4x from 2016 to 2025.

    P/S Ratio129.6x
    Forward P/S46.9x
    P/B Ratio5.9x
    P/TBV Ratio6.0x

    Valuation history and multiples

    Price Statistics

    The stock is up 4.48% over 52 weeks and trades 30.58% above its 50-day average.

    Beta (1Y)1.11
    52-Week Change+4.48%
    1-Month Change+44.52%
    3-Month Change+21.21%
    6-Month Change+88.23%
    5-Year Change+36.30%
    10-Year Change-69.46%
    Total Return (1Y)+4.48%
    Total Return (3Y CAGR)+23.70%
    Total Return (5Y CAGR)+8.88%
    Return vs SPY (1Y)-6.42%
    Max Drawdown (1Y)-60.63%
    Max Drawdown (3Y)-60.63%
    Sharpe Ratio (1Y)0.07
    Correlation with SPY (1Y)0.20
    50-Day Average$23.02
    200-Day Average$21.52
    52-Week Range$13.18 to $34.29
    RSI (14 Days)70.1
    Average Volume (20 Days)2.85M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 14.46x current liabilities, and total debt is 0.42x shareholder equity.

    Current Ratio14.46x
    Quick Ratio14.46x
    Debt / Equity0.42x
    Interest Coverage-15.75x

    Returns and Efficiency

    Return on invested capital is -41.75% over the last 12 months, against a 5-year average of -36.78%.

    Return on Equity (ROE)-78.11%
    Return on Assets (ROA)-44.09%
    Return on Invested Capital (ROIC)-41.75%
    Return on Capital Employed (ROCE)-45.43%
    ROE (5Y Average)-43.32%
    ROA (5Y Average)-38.35%
    ROIC (5Y Average)-36.78%
    Asset Turnover0.03x
    Inventory Turnover49.06x
    Receivables Turnover0.50x
    Cash Conversion Cycle-837 days

    Scores

    VRDN has an Altman Z-Score of 2.02, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score2.02
    Altman Z ZoneGrey
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $26.31M over the last 12 months is down 62.83% from the 12 months before.

    Revenue$26.31M
    Revenue Growth (YoY)-62.83%
    Gross Profit$24.46M
    Operating Income-$468.66M
    Pretax Income-$453.58M
    Net Income-$453.58M
    EBITDA-$434.77M
    EBIT-$435.47M
    Reported EPS (TTM)-$3.84

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 56.38% of the $1.03B in total assets.

    Cash and Equivalents$172.86M
    Total Debt$243.27M
    Net Debt$70.41M
    Net Debt Per Share$0.62
    Working Capital$943.08M
    Shareholder Equity$580.70M
    Book Value Per Share$5.12
    Tangible Book Value$570.91M
    Tangible Book Per Share$5.03
    Total Assets$1.03B
    Total Liabilities$447.97M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $1.94M of capital spending, operating cash flow left -$343.44M of free cash flow.

    Operating Cash Flow-$341.50M
    Capital Expenditures$1.94M
    Free Cash Flow-$343.44M
    FCF Per Share-$3.02
    Depreciation and Amortization$701.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -1781.38%.

    Gross Margin92.98%
    Operating Margin-1781.38%
    Pretax Margin-1724.06%
    Net Margin-1724.06%
    EBITDA Margin-1652.55%
    EBIT Margin-1655.22%
    FCF Margin-1305.42%

    Growth

    Revenue grew 241.95% a year over 3 years.

    Revenue Growth (3Y CAGR)+241.95%
    Revenue Growth (5Y CAGR)+132.18%
    Book Value Per Share Growth (2Y CAGR)-2.17%
    Tangible Book Per Share Growth (2Y CAGR)-2.17%

    Revenue and profit by year

    Dividends and Yields

    VRDN does not pay a dividend. Its free cash flow yield is -10.07%.

    FCF Yield-10.07%
    Shareholder Yield0.00%

    Stock Splits

    The last split was a 1-for-15 reverse split on Nov 13, 2020.

    Last Split DateNov 13, 2020
    Split TypeReverse split
    Split Ratio1:15

    Peer Position

    Against 8 similar companies, VRDN has the 3rd highest P/S.

    P/S Ratio129.6x vs 9.1x median
    ROIC-41.75% vs -29.73% median
    Revenue Growth (Trailing 4 Quarters, YoY)-62.83% vs +49.38% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 110.08% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+110.08%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About VRDN

    What is VRDN's market cap?

    Viridian Therapeutics has a market cap of $3.51B. Its enterprise value, which adds debt and subtracts cash, is $3.58B.

    How many shares of VRDN are outstanding?

    Viridian Therapeutics has 113.41M shares outstanding. The count is up 38.67% from a year earlier.

    Does VRDN pay a dividend?

    No. Viridian Therapeutics does not pay a dividend.

    How much debt does VRDN have?

    Viridian Therapeutics has $243.27M of total debt and $172.86M of cash and equivalents, a net debt position of $70.41M.